Health Care · Pharmaceutical Preparations

ALMS ALUMIS INC. SEC Filings & Insider Trading Activity 2026

company
CIK 184736769 filings
Russell 2000

ALMS at a glance

ALUMIS INC. (ALMS, SEC CIK 1847367) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), ALUMIS INC. (ALMS) reported revenue of $24.1 million and a net loss of $243.3 million. Diluted EPS was -$2.86.
  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding ALUMIS INC. (ALMS) shares worth $245.5 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Goldstein David M on November 2, 2026 of 629 shares at $6.52 per share.
  • In the last 90 days, ALMS insiders reported 4 open-market purchases ($10.7M) and 8 open-market sales ($1.0M) on Form 4, a net purchase of $9.7M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$24.1M
10-K XBRL
Insiders · 90 days
4 buys · 8 sells
Net +$9.7M
13F holders
25 funds
$245.5M · +0 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $1.9M, down 8% YoY from $2.1M, entirely collaboration revenue
  • Net loss $94.9M vs $110.8M YoY, operating loss $99.1M vs $115.3M
  • Envu, best-performing program: external R&D costs $42.0M vs $48.9M YoY
  • Operating cash use $248.2M for nine months, down from $297.6M; financing provided $367.2M
  • Cash, equivalents and marketable securities $431.3M, insufficient for 12 months; NDA submission planned by end of 2026

Risk Factors

  • Newly highlighted trade risk: 10% baseline tariff and Section 232 pharmaceutical-ingredient tariffs threaten overseas supply costs and clinical timelines
  • Most material clinical update: envu Phase 2b SLE trial failed primary and secondary endpoints in September 2026
  • Regulatory risk: EU Pharma Package could reduce data protection and facilitate earlier generic or biosimilar entry after anticipated 2028 implementation
  • Financial risk: $431.3 million liquidity insufficient for at least 12 months, with $94.9 million quarterly net loss
  • Commercial risk: envu faces approved and late-stage oral competitors across psoriasis and systemic lupus erythematosus indications

AI summary of the ALMS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Alumis fiscal quarter ended September 30, 2026
  • Exhibit 99.1 contains the company’s financial results and accompanying management disclosures

Item EX-99.1: Item EX-99.1

  • Q3 revenue $1.9M versus $2.1M, while net loss improved to $94.9M from $110.8M
  • Cash, equivalents and marketable securities $431.3M, supporting operations and capital needs into Q4 2027
Filed Sep 1, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • LUMUS Phase 2b missed primary and secondary endpoints in the overall 408-patient SLE population, weakening near-term lupus prospects
  • Prespecified IFNGS-high subgroup showed robust BICLA, CLASI-50, SRI-4, and LLDAS responses, supporting planned Phase 3 regulatory discussions

Item 8.01: Other Events

  • September 1, 2026 disclosure covers envudeucitinib Phase 2b LUMUS topline results in systemic lupus erythematosus
  • Planned NDA submission in fourth quarter 2026 creates a key regulatory catalyst

Item EX-99.2: Item EX-99.2

  • LUMUS Phase 2b missed primary and secondary endpoints overall, materially weakening envudeucitinib’s broad SLE development case
  • IFNGS-high subgroup showed stronger efficacy, including BICLA response rates of 40.7% to 52.6% versus 28.6% placebo
Filed Aug 13, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • ONWARD3 showed 54% PASI 100 and 75% PASI 90 at 48 weeks, strengthening envudeucitinib’s psoriasis commercial positioning
  • FDA NDA submission for moderate-to-severe plaque psoriasis remains targeted for Q4 2026, a key regulatory catalyst

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Alumis financial results for quarter ended June 30, 2026
  • Exhibit 99.1 contains the underlying results and management commentary for investor review

AI summaries of ALMS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ALMS

Don't miss the next ALMS filing

  • Alerts as it files. A push when ALMS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ALMS, by share count.
  • Ask anything. An AI agent that reads every ALMS filing and answers with sources.

ALMS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Goldstein David MSellNov 2, 2026$6.52
Drappa JornSellNov 2, 2026$6.52
Hardiman Roy C.SellNov 2, 2026$6.52
Bradley Mark ChristopherSellNov 2, 2026$6.52
Pangali SanamSellNov 2, 2026$6.52
Schroer John R.SellNov 2, 2026$6.52
AKKARAJU SRINIVASSellSep 8, 2026$10.55
AKKARAJU SRINIVASBuySep 8, 2026$10.63

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue--$24.1M
Operating Income-$158.2M-$300.8M-$453.8M
Net Income--$294.2M-$243.3M
Op. Margin---1886.9%
Net Margin---1011.7%
Balance Sheet
Total Assets$89.6M$341.0M$411.9M
Equity-$339.3M$260.1M$301.3M
ROE--113.1%-80.8%
Per Share
EPS-$-10.38$-2.86
Cash Flow
Operating CF-$130.0M-$255.1M-$369.5M
CapEx$4.5M$1.7M$653K

Source: XBRL data in ALUMIS INC. (ALMS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ALMS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ALMS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$245.5M
Q2 202625$1.01B
Q1 202626$580.2M
Q4 202523$143.6M
Q3 202522$51.7M
Q2 202522$34.4M
Q1 202514$10.7M
Q4 20248$9.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 165 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ALMS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 12, 2026Analysis
8-KNov 12, 2026Analysis-
4Nov 4, 2026--
4Nov 4, 2026--
4Nov 4, 2026--
4Nov 4, 2026--
4Nov 4, 2026--
4Nov 4, 2026--
4Sep 9, 2026--
8-KSep 1, 2026Analysis-
SC 13DAug 17, 2026-
10-QAug 13, 2026Analysis
8-KAug 13, 2026Analysis-
8-KAug 10, 2026Analysis-
SC 13GAug 6, 2026-
4Aug 5, 2026--
4Aug 5, 2026--
4Aug 5, 2026--
4Aug 5, 2026--
4Aug 5, 2026--
4Aug 5, 2026--
SC 13GJul 27, 2026-
4Jul 8, 2026--
8-KJul 2, 2026Analysis-
4Jul 2, 2026--

Related Health Care companies

All Health Care →

ALMS SEC filings: frequently asked questions

Are ALMS insiders buying or selling?

In the last 90 days, ALUMIS INC. (ALMS) officers, directors and 10% owners reported 4 open-market purchases worth $10.7 million by 1 insider and 8 open-market sales worth $1.0 million by 7 insiders on Form 4, a net purchase of $9.7 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ALMS stock?

As of September 30, 2026, the largest ALUMIS INC. (ALMS) holders among the 13F filers tracked by SignalX were BlackRock ($63.4 million), Vanguard Capital Management LLC ($31.5 million), Millennium Management ($24.6 million), State Street Corp ($21.8 million), Citadel Advisors LLC ($17.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ALMS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), ALUMIS INC. (ALMS) reported revenue of $24.1 million and a net loss of $243.3 million. Diluted EPS was -$2.86. The figures come from the XBRL data in the 10-K.

What did ALMS report in its latest 8-K?

ALUMIS INC. (ALMS) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Alumis fiscal quarter ended September 30, 2026.

What are the latest ALMS SEC filings?

ALUMIS INC. (ALMS) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 4, 2026.

What is ALMS's SEC CIK number?

ALUMIS INC. (ALMS)'s SEC Central Index Key (CIK) is 1847367. EDGAR lists every ALMS filing under that number.

Ask anything about ALMS

The research agent reads ALMS's filings, financials, insider trades and 13F holders, then answers with sources.